Updated labels change the conversation, not the need for careful screening The headline change sounds reassuring at first glance, but the article makes clear that blood pressure monitoring now deserves more attention, not…
MASH pipeline news matters most when it improves how decisions get made Combination regimens are drawing attention because single-pathway drugs often improve part of the picture without fully addressing fibrosis risk. Headlines around…
When an Add-On Sounds Better Than It Performs Why a second satiety signal may add less than headlines imply once GLP-1 treatment is already in place How nausea, dose limits, and tolerability can…
Why Visceral Fat Calls for a Different Conversation How organ-centered fat differs from subcutaneous fat when metabolic risk is the real concern Why early research in targeted fat pathways still needs careful interpretation…
A Daily Pill Changes the Routine, Not the Need for Structure How oral semaglutide differs from weekly injections in timing, absorption, and day-to-day consistency Why step-up dosing and empty-stomach rules can shape both…
Better Weight Loss Means Protecting More Than Fat Loss Alone Why fast results can come with a quieter tradeoff when lean mass drops alongside body fat How muscle-preserving strategies may matter most for…
Promising Research Still Needs Clinical Distance Why obesity-linked cancer biology has pushed metabolic therapies into a more serious scientific conversation What tumor-slowing signals in early studies can suggest, and what they still cannot…
A Label Change Does Not Replace Individual Risk Review Why the 2025 FDA shift changes the conversation around menopausal hormone therapy without removing the need for careful screening How timing, formulation, and route…
When menopause symptoms return after cancer treatment, the path forward needs nuance Older hormone studies still shape today’s caution, even as newer expert consensus pushes for more individualized risk review. Non-hormonal care and…
Weight-loss care is expanding well beyond the incretin pathway FGF21 and GDF15 analogs are drawing attention because they target metabolism, appetite signaling, and liver fat through different biologic routes. This matters most for…